Abbott to ship portable, 5-minute coronavirus tests nationwide

The FDA said Abbott's system can be used to test swabs directly—taken from the patient’s nose or throat straight to the machine. (Abbott)

Abbott is launching a rapid coronavirus test able to deliver positive results in as little as five minutes from a tabletop box the size of a small toaster oven.

Weighing less than seven pounds, the company’s ID NOW diagnostic can be run just about anywhere, inside or outside of a hospital. The portable point-of-care platform has been widely used to process quick strep throat and flu tests in physicians’ offices, emergency rooms and urgent care clinics. 

The FDA granted the molecular system an emergency authorization for use against COVID-19, and Abbott said it is currently ramping up production with plans to deliver 50,000 tests per day starting next week.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Abbott previously received an agency green light for a high-throughput COVID-19 test on its m2000 RealTime hardware. Between the two systems, the company said it’s aiming to produce about 5 million tests in April.

RELATED: With new FDA approval, Abbott sets goal of shipping 1 million coronavirus tests per week

Former FDA Commissioner Scott Gottlieb described the test as a game changer on Twitter, adding that additional diagnostics for doctors' offices and point of care are “very likely” to follow.

The FDA said the system can be used to test swabs directly—taken from the patient’s nose or throat straight to the machine—as well as nasal, nasopharyngeal or throat swabs stabilized in viral transport media.

At the same time, the agency granted an authorization to Luminex’s NxTAG CoV Extended panel assay, capable of processing 96 samples in four hours and detecting the novel coronavirus as well as 20 other common respiratory pathogens.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.